Skip to main content
  • DanGer Shock Trial: Abiomed’s Impella Pump Increases Survival Rates at 6 Months

    Implantation of the Impella CP micro-axial flow pump after a heart attack significantly increased survival rates at 6 months in people suffering cardiogenic shock, the DanGer Shock Trial concludes.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details